GE HealthCare’s SOFIE deal deepens a complicated relationship with Lantheus

GE HealthCare announced a $945 million acquisition of SOFIE Biosciences, a move analysts interpret as securing supply chain control for Flurcarbo, a cardiac PET imaging agent. The deal reflects competitive positioning in the nuclear imaging market and GE HealthCare's strategy to reduce dependence on external suppliers for critical radiopharmaceutical components used in cardiac diagnostics.